Test whether amyloid PET imaging will lead to a ≥ 30% change between intended and actual patient management within 90 days in a composite measure consisting of the following: a) AD drug therapy; b) Other drug therapy; or c) Counseling about safety and future planning.

August 09, 2017

  • Clinical Trial Information

    Trial Contact: Smuckler, David

    Trial Phone:

  • Age Group: Adult

    Phase: Not applicable

    Principal Investigator: David Todd Smuckler, MD

    Sub Investigators: N/A

    IRB No: 16.057.05

    Secondary Protocol No:

    Applicable Disease Sites: Brain